BioSim™ anti-Rituximab (Mabthera®) (Human) ELISA Kit

Rituximab (Mabthera®) is a genetically engineered chimeric murine/human monoclonal antibody specific to CD20. CD20 is an approximately 35 KDa transmembrane phosphoprotein involved in the activation, proliferation, and differentiation of B-lymphocytes. It is absent in terminally differentiated plasma cells. The Fab domain of rituximab binds to the CD20 antigen on B-lymphocytes and the Fc domain recruits immune effector functions to induce apoptosis in B cells. It is used in treating leukemias and lymphomas, some autoimmune disorders, and organ transplant. However, some patients develop unwanted immunogenicity, which leads to production of anti-drug-antibodies (ADAs) inactivating the therapeutic effects of the treatment and, in rare cases, inducing adverse effects. BioVision’s BioSimTM anti-Rituximab ELISA kit is designed to quantify/measure the antibody against Rituximab with high specificity and sensitivity in biological matrices.

Alternate Name: N/A

Tag Line: A Sandwich ELISA kit for the quantitative measurement of antibody against Rituximab in human serum or plasma.

Summary: • Detection method- Absorbance (450 nm) • Species reactivity- Human • Application- quantitative measurement of antibody against Rituximab in human serum and plasma

Detection Method: Absorbance (450 nm)

Sample Type: Human serum and plasma

Species Reactivity: Human

Applications: This ELISA kit is used for quantitative measurement of antibody against Rituximab in human serum and plasma

Features & Benefits: Easy, convenient, sensitive and time-saving method to measure the level of antibody against Rituximab in human serum and plasma. Detection Range: 62 - 500 ng/ml Sensitivity: 30 ng/ml Assay Precision: Intra-Assay: CV < 15%; Inter-Assay: CV < 15% (CV (%) = SD/mean X 100) Cross Reactivity: Rituximab (Rituxan®, Mabthera®) infusion camouflages/masks the presence of antibody to rituximab (ATR) in serum/plasma samples. Therefore, blood sampling time is critical for detection of ATR. It is convenient to obtain blood sample just before the infusion or at least 2 weeks after the infusion of Rituximab (Rituxan®, Mabthera®) Recovery rate: 85 – 115% with normal human serum samples with known concentrations